Authors: Se Yong Jung, Min Seo Kim, Han Li, Keum Hwa Lee, Ai Koyanagi, Marco Solmi, Andreas Kronbichler, Elena Dragioti, Kalthoum Tizaoui, Sarah Cargnin, Salvatore Terrazzino, Sung Hwi Hong, Ramy Abou Ghayda, Nam Kyun Kim, Seo Kyoung Chung, Louis Jacob, Joe-Elie Salem, Dong Keon Yon, Seung Won Lee, Karel Kostev, Ah Young Kim, Jo Won Jung, Jae Young Choi, Jin Soo Shin, Soon-Jung Park, Seong Woo Choi, Kiwon Ban, Sung-Hwan Moon, Yun Young Go, Jae Il Shin, Lee Smith
Venue: Clinical and Translational Science
Type: Publication
Abstract: On October 2020, the US Food and Drug Administration (FDA) approved remdesivir as the first drug for the treatment of coronavirus disease 2019 (COVID-19), increasing remdesivir prescriptions worldwide. However, potential cardiovascular (CV) toxicities associated with remdesivir remain unknown. We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO). Disproportionality analyses of CV-ADRs associated with remdesivir we...
(read more)
Topics: 
Pharmacology
Internal medicine
Emergency medicine
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...